How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,534 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

142. Management of Cardiovascular Diseases during Pregnancy

antagonist MRHD Maximum recommended human dose MRI Magnetic resonance imaging MS Mitral stenosis mWHO Modified World Health Organization NSTE-ACS Non-ST-elevation acute coronary syndrome NSTEMI Non-ST-elevation myocardial infarction NT-proBNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association OAC Oral anticoagulant OHSS Ovarian hyperstimulation syndrome OR Odds ratio PAH Pulmonary arterial hypertension PAP Pulmonary arterial pressure PCI Percutaneous coronary intervention PE (...) fms-like tyrosine kinase 1 STEMI ST-elevation myocardial infarction SVT Supraventricular tachycardia TAPSE Tricuspid annular plane systolic excursion TdP Torsade de pointes TGA Transposition of the great arteries TR Tricuspid regurgitation UFH Unfractionated heparin UPA Ulipristal acetate VKA Vitamin K antagonist VSD Ventricular septal defect VT Ventricular tachycardia VTE Venous thrombo-embolism WCD Wearable cardioverter-defibrillator WPW Wolff–Parkinson–White 1. Preamble Guidelines summarize

2018 European Society of Cardiology

143. ESC/ESH Management of Arterial Hypertension

Rosuvastatin LDH Lactate dehydrogenase LDL-C LDL cholesterol LEAD Lower extremity artery disease LIFE Losartan Intervention For Endpoint reduction in hypertension LV Left ventricular LVH Left ventricular hypertrophy MAP Mean arterial pressure MI Myocardial infarction MR Magnetic resonance MRA Mineralocorticoid receptor antagonist MRI Magnetic resonance imaging MUCH Masked uncontrolled hypertension NORDIL Nordic Diltiazem NS Non-significant NT-proBNP N-terminal pro-B natriuretic peptide o.d. Omni die (every

Full Text available with Trip Pro

2018 European Society of Cardiology

144. Guidelines on Diagnosis and Management of Syncope

1914 5.2.5.2 Alpha-agonists 1914 5.2.5.3 Beta-blockers 1915 5.2.5.4 Other drugs 1915 5.2.5.5 Emerging new therapies in specific subgroups 1915 5.2.6 Cardiac pacing 1915 5.2.6.1 Evidence from trials in suspected or certain reflex syncope and electrocardiogram- documented asystole 1915 5.2.6.2 Evidence from trials in patients with carotid sinus syndrome 1915 5.2.6.3 Evidence from trials in patients with tilt-induced vasovagal syncope 1916 5.2.6.4 Evidence from trials in patients with adenosine

2018 European Society of Cardiology

145. Quinapril

-adrenergic signal transduction pathway (...) by the development of fulminant hypertension with cardiac hypertrophy. 2. Seven week old heterozygous TG(mREN2)27 rats were treated for 11 weeks with the AT1-receptor antagonist losartan (10 mg kg[-1]), the ACE-inhibitor quinapril (15 mg kg[-1]) and the direct vasodilator hydralazine (30 mg kg[-1]). Untreated TG and normotensive Sprague-Dawley rats (SD) served as controls. 3. TG(mREN2)27-rats were characterized by arterial hypertension (TG 194+/-3.2 mmHg vs SD (...) The purpose of this study is to compare the impact of two blood pressure lowering treatments (high dose quinapril 2006 3. Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies: Study Record Detail Effects of Quinapril 40 mg

2018 Trip Latest and Greatest

146. Nifedipine

beta 2 -adrenergic-receptor agonists and better tolerated compared with beta 2 -adrenergic-receptor (...) agonists and magnesium sulfate in women with preterm labour. The review was generally well conducted, but the authors’ conclusions regarding magnesium sulphate may be too strong given the small number of trials included in the analyses. Authors' objectives To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labour. Searching MEDLINE, EMBASE, LILACS, Web (...) of this study was to compare the effectiveness of nifedipine versus indomethacin 2011 10. Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker ( nifedipine ) and an alpha-blocker (tam Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost

2018 Trip Latest and Greatest

147. Latanoprost

of a new antiglaucoma drug lathanoprost, a 0.005% xalathane solution, prostaglandin F2 alpha analog, is studied. A single instillation of xalathane (...) Trial Perspektivy primeneniia analoga prostaglandina F2 al'fa latanoprosta v gipotenzivnoĭ terapii glaukomy. Russia (Federation) Vestn Oftalmol 0415216 0042-465X 0 Adrenergic beta-Antagonists 0 Ophthalmic Solutions 0 Parasympathomimetics 0 Prostaglandins F, Synthetic 01MI4Q9DI3 Pilocarpine 6Z5B6HVF6O latanoprost 817W3C6175 Timolol B7IN85G1HY Dinoprost (...) IM Adrenergic beta-Antagonists administration & dosage therapeutic use Chronic Disease Dinoprost analogs & derivatives Drug Therapy, Combination 1998 8. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA Record Status

2018 Trip Latest and Greatest

149. Doxazosin

participants. (see ) Verified September 2016 by VA Office of Research and Development Sponsor (...) of cocaine dependence; however, both animal and human studies suggest that medications affecting the noradrenergic system can reduce cocaine craving and use. The investigators will study the effect of doxazosin , an alpha-1 adrenergic antagonist, in reducing cocaine use and anxiety symptoms among cocaine-dependent individuals. In addition, the investigators will identify genetic subpopulations (...) of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: An observational study. To explore the safety and efficacy of the selective 5-serotonin and norepinephrine reuptake inhibitor duloxetine hydrochloride and alpha-adrenergic receptor blocker (alpha-blocker) doxazosin mesylate-controlled tablets in the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS (...) ).In all, 150 patients were

2018 Trip Latest and Greatest

150. Terazosin

Cooperative Studies Benign Prostatic Hyperplasia Study Group. 533-9 Men with benign prostatic hyperplasia can (...) be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared. We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs (...) Ravilla D RD eng Case Reports Letter India Indian J Ophthalmol 0405376 0301-4738 0 Adrenergic alpha-Antagonists 0 Platelet Aggregation Inhibitors 8L5014XET7 Terazosin XM03YJ541D 2007 11. Terazosin activated Pgk1 and Hsp90 to promote stress resistance 25383758 2014 12 18 2015 02 25 2017 02 20 1552-4469 11 1 2015 Jan Nature chemical biology Nat. Chem. Biol. Terazosin activates Pgk1 and Hsp90 to promote stress resistance. 19-25 10.1038/nchembio.1657 Drugs that can protect against organ damage

2018 Trip Latest and Greatest

151. Lack of alpha 1b-adrenergic receptor protects against epileptic seizures. (PubMed)

Lack of alpha 1b-adrenergic receptor protects against epileptic seizures. The role of alpha 1b-adrenergic receptor (alpha 1b-AR) in relation with neuronal degeneration, drug addiction, and seizure susceptibility has recently emerged. In particular, mice that overexpress alpha 1b-AR undergo spontaneous epileptic seizures and progressive neuronal loss in a variety of brain areas. Therefore, one should expect that the blockade of alpha 1b-AR leads to anticonvulsant and neuroprotective effects (...) . However, the lack of alpha 1b-AR antagonists does not allow testing of this hypothesis.The development of alpha 1b-AR knockout (KO) mice led us to measure seizure susceptibility and neurodegeneration following systemic excitotoxins in these mice.We found that alpha 1b-AR KO mice are markedly resistant to kainate- and pilocarpine-induced seizures. Moreover, when marked seizure duration and severity are obtained by doubling the dose of chemoconvulsants in alpha 1b-AR KO, neuronal degeneration never

Full Text available with Trip Pro

2009 Epilepsia

152. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

are employed to treat LUTS attributed to BPH, including alpha- adrenergic antagonists (alpha-blockers), beta adrenergic agonists, 5-alpha- reductase inhibitors (5- ARIs), anticholinergics, vasopressin analogs, PDE-5 inhibitors, and phytotherapeutics, which can be utilized alone or in combination to take advantage of their different mechanisms of action. Conversely, there exist clinical scenarios when either conservative management , including life style changes (e.g., fluid restriction, avoidance

2019 American Urological Association

153. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

are employed to treat LUTS attributed to BPH, including alpha-adrenergic antagonists (alpha-blockers), beta adrenergic agonists, 5-alpha- reductase inhibitors (5-ARIs), anticholinergics, vasopressin analogs, PDE-5 inhibitors, and phytotherapeutics, which can be utilized alone or in combination to take advantage of their different mechanisms of action. Conversely, there exist clinical scenarios when either conservative management , including life style changes (e.g., fluid restriction, avoidance (...) of renal deterioration if inadequately treated on medication. Long standing BOO from BPH can progress to incomplete bladder emptying, bilateral hydroureteronephrosis, and ultimately acute and/or chronic renal insufficiency. Although transient urethral catheterization with concomitant medical therapy using an alpha adrenergic antagonist can be considered, it is unlikely that the latter will adequately ameliorate the obstructive process to sufficiently prevent further upper urinary tract deterioration

2019 American Urological Association

155. Urolithiasis

., et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ, 2016. 355: i6112. 106. Guercio, S., et al. Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department. J Endourol, 2011. 25: 1137. 107. Ramsey, S., et al. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol, 2010. 24: 185. 108. Lynch, M.F., et (...) , 1994. 152: 1095. 114. Porpiglia, F., et al. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology, 2000. 56: 579. 115. Dellabella, M., et al. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology, 2005. 66: 712. 116. Campschroer, T., et al. Alpha-blockers as medical expulsive therapy

2019 European Association of Urology

157. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update

arousal systems. The same is true for any drug which blocks one of the other arousal systems; they produce a degree of sedation but are not generally e?ective hypnotics. However, someagentshavespeci?cactionsoncertainsleepparameters; for instance, drugs which block 5HT2 receptors (such as ritanserin or eplivanserin) can increase slow-wave sleep (Idzikowski et al., 1988; Landolt et al., 1999) whereas the alpha-1 adrenergic blocker prazosin is useful in post-trau- matic stress disorder-related nightmares (...) of proteins with bind- ing sites for a number of sleep-promoting drugs, in particu- lar benzodiazepines, so-called Z-drugs and barbiturates, all of which enhance the e?ects of GABA’s actions at the GABA A receptor. There are a number of subtypes of this receptor which are relevant for sleep, not only because of their di?erent location in the brain but also because of the fact that some hypnotic drugs are selective for a particular subtype. The alpha-1 subtype is highly expressed in the cortex and probably

2019 British Association for Psychopharmacology

158. Pruritus

33 6.4.3 Glucocorticosteroids 33 6.4.4 Opioid receptor agonists and antagonists 34 6.4.5 Gabapentin and pregabalin 35 6.4.6 Antidepressants 36 6.4.7 Serotonin receptor antagonists 38 6.4.8 Thalidomide 39 6.4.9 Leukotriene receptor antagonists and TNFa antagonists 39 6.4.10 Cyclosporine, methotrexate, azathioprine and tacrolimus 40 6.4.11 Neurokinin receptor 1 antagonist 41 6.4.12 Biologics 42 6.4.13 Physical treatment modalities 43 6.5 Ultraviolet phototherapy 45 6.6 Treament in special (...) -receptor opioid antagonists such as nalmefene and naltrexone supports the hypothesis that opioid receptors and a high opioid tone influences ChP (Bergasa, Schmitt et al. 1998). 11 4.1.4 Pruritus in metabolic and endocrine diseases In endocrine disorders such as hyperthyroidism and diabetes mellitus, less than 10% of patients report pruritus (Neilly, Martin et al. 1986, Jabbour 2003). In patients with hypothyroidism, pruritus is most probably driven by xerosis of the skin. Patients with primary

2019 European Dermatology Forum

159. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy

protein 20; VF = ventricular fibrillation; VT = ventricular tachycardia; SCN5A = sodium voltage-gated channel alpha subunit 5; TMEM43 = transmembrane protein 43. ---- | ---- Figure 4 Approach to understanding the common pathway and genetic variants in a patient with arrhythmogenic cardiomyopathy (ACM) according to the predominant ventricular dysfunction. See also Table 3 . ALVC = arrhythmogenic left ventricular cardiomyopathy; ARVC = arrhythmogenic right ventricular cardiomyopathy; BAG3 = BCL2 (...) associated athanogene 3; DSC2 = desmocollin-2; DSG2 = desmoglein-2; DSP = desmoplakin; FLNC = filamin-C; JUP = junction plakoglobin; KCNH2 = potassium voltage-gated channel subfamily H member 2; KCNQ1 = potassium voltage-gated channel subfamily Q member 1; LDB3 = LIM domain binding 3; LMNA = lamin A/C; NKX2-5 = NK2 homeobox 5; PKP2 = plakophilin-2; PLN = phospholamban; RBM20 = RNA binding motif protein 20; SCN5A = sodium voltage-gated channel alpha subunit 5; TMEM43 = transmembrane protein 43; TRPM4

2019 International Society for Heart and Lung Transplantation

160. Treatment for Acute Pain: An Evidence Map

several classes. Pain relieving analgesics include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen. These are often used in combination. Based on putative pain mechanisms, providers may also manage acute pain with muscle relaxants, antidepressants, alpha-2 agonists, GABA analogues, corticosteroids, NMDA receptor antagonists, local anesthetics, cannabinoids, among others. 23, 24 Topical agents such as capsaicin and lidocaine are also used. 23 Many medications for pain

2019 Effective Health Care Program (AHRQ)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>